Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

President Trump reportedly held a “fiery” call with Denmark’s Prime Minister Mette Frederiksen over the president’s insistence that U.S. control of Greenland is necessary for American ...

Trump has also questioned whether Denmark, which has controlled Greenland since 1814, has a "legal right" to the territory and predicted that Greenland's people will vote to join the U.S. He ...

Novo Nordisk A/S soared the most since August after an experimental shot delivered as much as 22% weight loss in an ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...

Novo Nordisk (NVO) shares traded sharply higher in European trading on Friday after the Danish drugmaker said amycretin, one of its novel obesity therapies, caused up to 22% of weight loss over 36 ...

As Alzheimer’s disease is the most common form of dementia — affecting an estimated 6.7 million Americans — it’s not surprising that people who experience memory loss may suspect AD.

Healthcare & Pharmaceuticalscategory Outgoing FDA chief flags online weight loss drug dangers January 17, 2025 Healthcare & Pharmaceuticalscategory Novo Nordisk says its obesity drug in higher ...

Establishing a nutritious, balanced diet is just as important as your workout routine to help with your weight loss goals. Research confirms this—a study published in The Journal of Strength and ...